Jens Wuerthner
About
Jens Wuerthner is a scholar working on Oncology, Molecular Biology and Genetics.
According to data from OpenAlex, Jens Wuerthner has authored 24 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Jens Wuerthner's work include HER2/EGFR in Cancer Research (7 papers), CAR-T cell therapy research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Jens Wuerthner is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), CAR-T cell therapy research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Jens Wuerthner collaborates with scholars based in United States, United Kingdom and Switzerland. Jens Wuerthner's co-authors include Hans G. Cruz, Jay Feingold, Joseph Boni, Ensar Halilovic, Sébastien Jeay, Alexander I. Spira, Graham P. Collins, Mehdi Hamadani, Tobias Menne and Steven M. Horwitz and has published in prestigious journals such as Blood, Cancer Research and British Journal of Cancer.
In The Last Decade
Jens Wuerthner
23 papers receiving 335 citations
Peers
Jens Wuerthner
Jennifer Kimberly Lue United States
Bing Xiu China
Lorena Barclay Canada
Elizabeth Carideo United States
Beverly J. Lynch United States
Boris G. Naraev United States
Elisa Mandato Italy
Santiago Barrio Spain
Heidi Nauwelaerts Switzerland
M. Nieves Calvo-Vidal United States
Citations per year, relative to Jens Wuerthner Jens Wuerthner (= 1×)
peers
Jennifer Kimberly Lue
Countries citing papers authored by Jens Wuerthner
Since
Specialization
Citations
This map shows the geographic impact of Jens Wuerthner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Wuerthner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Wuerthner more than expected).
Fields of papers citing papers by Jens Wuerthner
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jens Wuerthner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Wuerthner. The network helps show where Jens Wuerthner may publish in the future.
Co-authorship network of co-authors of Jens Wuerthner
This figure shows the co-authorship network connecting the top 25 collaborators of Jens Wuerthner. A scholar is included among the top collaborators of Jens Wuerthner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Wuerthner. Jens Wuerthner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Revuelta, María V., Nahuel Zamponi, Eloisi Caldas-Lopes, et al.. (2023). Qpctl Inhibition, By Targeting the Inflammatory Tumor Microenvironment, Constitutes a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma. Blood. 142(Supplement 1). 49–49.
2.
Wuerthner, Jens, Karin Havenith, Mehdi Hamadani, et al.. (2022). Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology. 91(1). 13–24.
3.
Boni, Joseph, et al.. (2022). Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology. 91(1). 1–12.
4.
Herrera, Alex F., Carmelo Carlo‐Stella, Pier Luigi Zinzani, et al.. (2022). CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood. 140(Supplement 1). 9306–9308.
5.
Bauer, Sebastian, George D. Demetri, Ensar Halilovic, et al.. (2021). Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. British Journal of Cancer. 125(5). 687–698.
6.
Hamadani, Mehdi, Graham P. Collins, Paolo F. Caimi, et al.. (2021). Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. The Lancet Haematology. 8(6). e433–e445.
7.
Zinzani, Pier Luigi, Carmelo Carlo‐Stella, Mehdi Hamadani, et al.. (2021). CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL). Hematological Oncology. 39(S2).
8.
Herrera, Alex F., Carmelo Carlo‐Stella, Graham P. Collins, et al.. (2020). Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 136(Supplement 1). 21–23.
9.
Goldberg, Aaron D., Ehab Atallah, David A. Rizzieri, et al.. (2020). Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leukemia Research. 95. 106385–106385.
10.
Puzanov, Igor, Karin Havenith, Joseph Boni, et al.. (2020). 1030P First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation. Annals of Oncology. 31. S710–S711.
11.
Boni, Joseph, Karin Havenith, Mehdi Hamadani, et al.. (2020). Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma. Blood. 136(Supplement 1). 35–36.
12.
Collins, Graham P., Steven M. Horwitz, Mehdi Hamadani, et al.. (2019). ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL). Hematological Oncology. 37(S2). 95–97.
13.
Collins, Graham P., Steven M. Horwitz, Andrew Davies, et al.. (2018). Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma. Blood. 132(Supplement 1). 1658–1658.
14.
Hamadani, Mehdi, Graham P. Collins, Felipe Samaniego, et al.. (2018). Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma. Blood. 132(Supplement 1). 928–928.
15.
Abila, Bams, et al.. (2018). Current Trends in the Clinical Development of Antibody-Drug Conjugates in Oncology. Pharmaceutical Medicine. 32(4). 259–273.
16.
Horn, Thomas, Stéphane Ferretti, Nicolas Ebel, et al.. (2016). High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. Cancer Research. 76(23). 6950–6963.
17.
Bauer, Sebastian, George D. Demetri, Sébastien Jeay, et al.. (2016). A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors. Annals of Oncology. 27. vi116–vi116.
18.
Nölting, Svenja, Sabine Herterich, Stefanie Hahner, et al.. (2016). The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53<sup>wild type</sup> Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology. 106(1). 1–19.
19.
Townsend, Elizabeth C., Tiffany DeSouza, Mark A. Murakami, et al.. (2015). The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts. Blood. 126(23). 797–797.
20.
Wang, Hui Qin, Matthew Zubrowski, Erling O. Emerson, et al.. (2014). Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma. Cancer Research. 74(19_Supplement). 5466–5466.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jennifer Kimberly Lue Breakdown of academic impact, for papers by Bing Xiu Breakdown of academic impact, for papers by Lorena Barclay Breakdown of academic impact, for papers by Elizabeth Carideo Breakdown of academic impact, for papers by Beverly J. Lynch Breakdown of academic impact, for papers by Boris G. Naraev Breakdown of academic impact, for papers by Elisa Mandato Breakdown of academic impact, for papers by Santiago Barrio Breakdown of academic impact, for papers by Heidi Nauwelaerts Breakdown of academic impact, for papers by M. Nieves Calvo-Vidal